Name | (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum(II) |
Synonyms | DACHPM Miripla SM-11355 SM 11355 SMP-11355 Miriplatin DACHPt(II)(Myr)2 [(1R,2R)-1,2-Cyclohexanediamine]bis(myristato)platinum (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis... (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum(II) |
CAS | 141977-79-9 |
Molecular Formula | C34H66N2O4Pt |
Molar Mass | 762 |
Solubility | 10 mM in DMSO |
Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
In vitro study | Miriplatin (SM-11355) suspended in LPD (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis. |
In vivo study | Miriplatin (SM-11355) (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells. Miriplatin/LPD (400 μg/head) significantly reduces the growth of tumor in rats bearing AH109A cells. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.309 ml | 6.545 ml | 13.089 ml |
5 mM | 0.262 ml | 1.309 ml | 2.618 ml |
10 mM | 0.131 ml | 0.654 ml | 1.309 ml |
5 mM | 0.026 ml | 0.131 ml | 0.262 ml |
function and use | mitoplatin is a platinum anticancer drug developed by Sumitomo Pharmaceutical Co., Ltd., with a freeze-dried powder injection specification of 70mg/branch, which is effective in treating liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer. Its mechanism of action is similar to that of other platinum drugs. It acts on DNA by producing alkylated conjugates to form intra-strand and inter-strand crosslinking, thereby inhibiting DNA synthesis and replication, and inhibiting tumor growth. Animal studies have shown that, after TACE, misaplatin suspension can target the accumulation of sustained-release active ingredients in tumor tissues, exerting a good anti-tumor effect, and its anti-cancer activity is better than that of Jingstadinosilate. Clinical studies have shown that the TEV ratios of the mitaplatin group and the jingstoastatin group are 26.5%(22/83) and 17.9%(7/39), respectively; the 2-year survival rates of the two groups are 75.9 and 70.3%, respectively; 3 The year survival rate is 58.4% and 48.7%, respectively, and the two drugs have similar effects. Compared with jingostatin, no hepatic vascular injury was found in the milaplatin group (without affecting retreatment), and the irreversible injury to the hepatobiliary system (adversely affecting the prognosis) was reduced, and the safety was better than that of jingostatin. Moplatin is an anti-cancer drug that is dissolved in the special iodized poppy seed oil fatty acid ethyl ester and administered in the hepatic artery. It has a high affinity with the iodized poppy seed oil fatty acid ethyl ester, and is administered in the hepatic artery After staying in the tumor site, the platinum component in the suspension can be slowly released into the blood or tissue for a long time. The platinum divalent compound binds to DNA to inhibit the proliferation of cancer cells by preventing DNA synthesis and improving the anti-cancer effect. Clinical trials have shown that this product has shown good anti-cancer effects whether it is the first time for patients with hepatocellular carcinoma or some relapsed patients who have undergone liver resection and other treatments. |
Biological activity | Miriplatin (SM-11355) is a derivative of cisplatin containing myristate as a carrier ligand. It is a novel lipophilic platinum complex for the treatment of hepatocellular carcinoma. |